Abstract:Constitutive activation of cyclin-dependent kinases (CDKs) or arginine auxotrophy are hallmarks of Glioblastoma multiforme (GBM). The latter metabolic defect renders tumor cells vulnerable to arginine-depleting substances, such as arginine deiminase from Streptococcus pyogenes (SpyADI). Previously, we confirmed the susceptibility of patient-derived GBM cells towards SpyADI as well as CDK inhibitors (CDKis). To improve therapeutic effects, we here applied a combined approach based on SpyADI and CDKis (dinaciclib, abemaciclib). Three arginine-auxotrophic patient-derived GBM lines with different molecular characteristics were cultured in 2D and 3D and effects of this combined SpyADI/CDKi approach were analyzed in-depth. All CDKi/SpyADI combinations yielded synergistic antitumoral effects, especially when given sequentially (SEQ), i.e., CDKi in first-line and most pronounced in the 3D models. SEQ application demonstrated impaired cell proliferation, invasiveness, and viability. Mitochondrial impairment was demonstrated by increasing mitochondrial membrane potential and decreasing oxygen consumption rate and extracellular acidification rate after SpyADI/abemaciclib monotherapy or its combination regimens. The combined treatment even induced autophagy in target cells (abemaciclib/SpyADI > dinaciclib/SpyADI). By contrast, the unfolded protein response and p53/p21 induced senescence played a minor role. Transmission electron microscopy confirmed damaged mitochondria and endoplasmic reticulum together with increased vacuolization under CDKi mono- and combination therapy. SEQ-abemaciclib/SpyADI treatment suppressed the DSB repair system via NHEJ and HR, whereas SEQ-dinaciclib/SpyADI treatment increased γ-H2AX accumulation and induced Rad51/Ku80. The latter combination also activated the stress sensor GADD45 and β-catenin antagonist AXIN2 and induced expression changes of genes involved in cellular/cytoskeletal integrity. This study highlights the strong antitumoral potential of a combined arginine deprivation and CDK inhibition approach via complex effects on mitochondrial dysfunction, invasiveness as well as DNA-damage response. This provides a good starting point for further in vitro and in vivo proof-of-concept studies to move forward with this strategy.

EXTH-39. BIOMARKER DRIVEN TARGETING OF RECURRENT IDH MUTANT GLIOMA WITH ABEMACICLIB

EXTH-55. TARGETING RECURRENT IDH MUTANT GLIOMA WITH CDK4/6 INHIBITION

CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition

Ctni-58. A Phase 0/2 Trial Of Abemaciclib Plus Ly3214996 In Recurrent Glioblastoma

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells

Ctim-07. A Phase Ii, Open Label, Single Arm Study Of Nivolumab For Recurrent Or Progressive Idh Mutant Gliomas With Prior Exposure To Alkylating Agents

Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme

Biom-12. Alliance A071401: Genomically Guided Phase Ii Trial Of Abemaciclib In Patients With Grade 2/3 Meningiomas Harboring Somatic Nf2 Or Cdk Pathway Alterations

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

EXTH-19. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA

Ctim-28. Neoadjuvant Anti-Pd1 Immunotherapy For Surgically Accessible Recurrent Glioblastoma: Clinical And Molecular Outcomes Of A Stage 2 Single-Arm Expansion Cohort

DDEL-08. NOVEL COMBINATION THERAPY USING PI3KINASE INHIBITION AND IMMUNE BASED THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

BSTM-01. POTENT ANTI-TUMOR EFFICACY OF PALBOCICLIB IN TREATMENT-NAÏVE H3.3K27M-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

CBMT-31. HDAC INHIBITION DIMINISHES THE GROWTH OF ENDOGENOUS IDH MUTANT GLIOMAS

Genetic Aberrations in the CDK4 Pathway and Association with Innate Resistance to PD-1 Blockade in Acral Melanoma.

Csig-25. Mapk/Erk Signaling In Gliomas Modulates Interferon Responses, Promotes Tumor-Microglia Crosstalk, And Confers Susceptibility To Anti-Pd-1 And Anti-Ctla-4 Immunotherapy